Related by context. All words. (Click for frequent words.) 83 Genasense ® 82 Ganite R 76 Ganite ® 71 Ganite 69 YONDELIS 68 EOquin TM 68 Cutaneous T 67 Pemetrexed 67 Advanced Renal Cell 67 Fludara ® 67 docetaxel Taxotere ® 67 Phase III Trial 67 Hormone Refractory Prostate Cancer 67 Pivotal Phase III 66 Patients Treated With 66 Antitumor Activity 66 Gemzar ® 66 Advanced Melanoma 66 erlotinib Tarceva ® 66 Genasense 66 Meets Primary Endpoint 65 Bevacizumab 65 Metastatic Colorectal Cancer 65 ™ pralatrexate injection 65 Metastatic Melanoma 65 refractory chronic lymphocytic 65 Orphan Drug Status 65 dasatinib Sprycel ® 65 Initiate Clinical Trial 65 Amrubicin 65 Fast Track Status 65 sorafenib tablets 65 TORISEL 65 Combination REOLYSIN R 65 Raptiva ® 65 Ecallantide 65 Pralatrexate 65 Campath ® 65 Receives Orphan Drug Designation 65 Granted Orphan Drug 65 Aflibercept 65 Wafer polifeprosan 65 ThermoDox R 65 Phase 2b Clinical Trial 65 Civacir 65 Glufosfamide 65 oropharyngeal candidiasis 64 Hsp# Inhibitor 64 Pirfenidone 64 Newly Diagnosed Multiple Myeloma 64 Tamibarotene 64 MOZOBIL 64 Paraplatin ® 64 PEGylated anti 64 Albuferon TM 64 Cloretazine ® 64 Oral Fingolimod 64 Pivotal Trial 64 Perifosine 64 Ixempra 64 Completes Patient Enrollment 64 Phase III Clinical Trial 64 Kit CD# positive 64 induced macular edema 64 FOLOTYN ® 64 Clolar ® 64 NDA Submission 64 Panzem R 64 Methylnaltrexone 64 LEUKINE 64 Sapacitabine 64 evaluating picoplatin 64 HDAC Inhibitor 64 Atypical Hemolytic Uremic Syndrome 64 IgG1 monoclonal antibody 64 Microplasmin 64 Sevelamer 64 GW# [003] 64 Xelox 64 Combidex 64 IMiDs ® compound 64 Phase #b/#a clinical 64 Pivotal Phase 63 Vicinium TM 63 Investigational Treatment 63 Teva Provides Update 63 Lubiprostone 63 Xeloda ® 63 trastuzumab Herceptin R 63 Bortezomib 63 Romiplostim 63 Virulizin R 63 Severe Sepsis 63 C1 Inhibitor 63 R lenalidomide 63 Tibotec Therapeutics division 63 Bosutinib 63 Drug Candidate 63 SPRYCEL ® 63 metastatic GIST 63 #D#C# 63 unique alkylating agent 63 FASLODEX 63 Patient Enrollment 63 Temodar ® 63 Degarelix 63 Dasatinib 63 metastatic neuroendocrine tumors 63 Personalized Immunotherapy 63 BiovaxID TM 63 Cethromycin 63 PEGylated Fab fragment 63 TYZEKA 63 Boceprevir 63 R sorafenib tablets 63 Clinical Trial Results 63 Xcellerated T Cells 63 Pegloticase 63 Ceflatonin R 63 monoclonal antibody conjugated 63 Granulocyte Colony Stimulating Factor 63 myelodysplastic myeloproliferative diseases 63 Files IND 63 DOXIL 63 Initiates Enrollment 63 TNF Tumor Necrosis Factor 63 Randomized Phase 63 Brentuximab Vedotin SGN 63 Complicated Skin 63 IL# PE#QQR 63 UPLYSO 62 Prolongs Survival 62 Phase IIb Trial 62 VIVITROL ® 62 Phase 2a Trial 62 Receives Fast Track 62 PROSTASCINT R 62 Virulizin ® 62 Pivotal Study 62 MEK Inhibitor 62 REPLAGAL 62 sunitinib Sutent 62 Dapagliflozin 62 IRESSA 62 relapsed multiple myeloma 62 Orphan Drug status 62 STELARA TM 62 Immunotherapeutic 62 Dose Escalation 62 bevacizumab Avastin ® 62 Cellegesic 62 MyVax R 62 Xanafide 62 Zorbtive TM 62 Neupogen ® 62 Vandetanib 62 IMiDs 62 VALSTAR TM 62 refractory cutaneous T 62 monoclonal antibody IgG1 Mab 62 EGFR expressing mCRC 62 2 methoxyestradiol 62 Prospective Randomized 62 Orphan Status 62 Fondaparinux 62 refractory peripheral T 62 CCX# 62 castrate resistant prostate cancer 62 Pafuramidine 62 Initiates Clinical Trial 62 Phase III Pivotal 62 Survival Benefit 62 atypical Hemolytic Uremic Syndrome 62 including eniluracil ADH 62 SinuNase TM 62 CoreValve System 62 Argatroban 62 metastatic castrate resistant 62 INTEGRILIN R 62 Pivotal Clinical Trial 62 Previously Treated 62 Trial Evaluating 62 Initiate Phase III 62 Demonstrates Positive 62 RhuDex ® 62 Dacogen injection 62 AVASTIN 62 catheter occlusion 62 Onalta TM 62 Neulasta R 62 Ceflatonin ® 62 candidates Azedra TM 62 Peginterferon alfa 2b 62 rilonacept 62 PDX pralatrexate 62 Ofatumumab 62 sorafenib Nexavar 62 FIRMAGON 62 ONCASPAR 62 INCB# [003] 62 Golimumab 62 refractory multiple myeloma 62 Icatibant 61 AEG# 61 Receives Marketing Authorization 61 Kepivance 61 Nipent R 61 Besivance 61 Topotecan 61 Taxotere ® 61 Bezielle 61 interferon gamma 1b 61 Ridaforolimus 61 ZOLINZA 61 TREANDA 61 Pooled Analysis 61 ADVEXIN p# therapy 61 Dalbavancin 61 FUSILEV ® 61 Relapsed Multiple Myeloma 61 Study Evaluating 61 Receives Positive Opinion 61 Aplidin 61 Oral Calcitonin 61 DOXIL R 61 cinacalcet HCl 61 Medoxomil 61 Tarceva TM 61 Kuvan R 61 acyclovir Lauriad R 61 hyaluronidase enzyme 61 Orphan Drug designations 61 Panzem R NCD 61 Tavocept 61 NOXAFIL 61 arthritis PsA 61 Raptiva R 61 CYT# potent vascular disrupting 61 targeted radiotherapeutic 61 Improved Survival 61 recurrent NSCLC 61 5 Fluorouracil 61 XL# anticancer compounds 61 Phase III Trials 61 Aurexis 61 Ambrisentan 61 Aryplase 61 BYETTA ® 61 vinorelbine tartrate 61 Nexavar ® 61 oral ridaforolimus 61 Eraxis 61 Daclizumab 61 Allovectin 7 R 61 PrevOnco 61 Tezampanel 61 Long Term Efficacy 61 miconazole MBT 61 Archexin 61 sapacitabine CYC# 61 Initiates Phase III 61 hypereosinophilic syndrome 61 Is Well Tolerated 61 sarcoma melanoma 61 Natalizumab 61 Phase IIb Clinical Trial 61 BARACLUDE R 61 liposomal formulation 61 Vidaza azacitidine 61 Oracea TM 61 Diabetic Macular Edema 61 Regenerative Cells 61 CAELYX 61 intravesical infusion therapy 61 Belinostat 61 Gleevec Glivec 61 Investigational Compound 61 PGL# 61 Epratuzumab 61 Certican 61 EGFr expressing metastatic colorectal 61 HER2 Positive Breast Cancer 61 recurrent glioblastoma multiforme 61 CCX# B 61 refractory Hodgkin lymphoma 61 Targretin capsules 61 acetonide FA 61 IMiDs ® 61 bortezomib Velcade R 61 Silodosin 61 Moxifloxacin 61 Copegus ® 61 CRMD# 61 metastatic hormone refractory 61 Previously Untreated 61 TYKERB 61 HER2 positive metastatic breast 61 FDA Accepts 61 ABILIFY ® 61 ZEVALIN ® 61 FOLFOX6 chemotherapy regimen 61 orally administered inhibitor 60 bortezomib Velcade 60 OvaRex ® MAb 60 MAGE A3 ASCI 60 Crofelemer budesonide foam 60 Peginterferon 60 Belimumab 60 PROVENGE ® 60 methylnaltrexone bromide 60 Milatuzumab 60 Camptosar ® 60 Voreloxin 60 HuMax CD4 60 Navelbine ® 60 histone deacetylase HDAC inhibitor 60 BENLYSTA ® 60 phase IIb clinical 60 Oracea ® 60 Monotherapy 60 Safinamide 60 Receives Orphan Drug 60 gefitinib Iressa 60 Phase Ib IIa 60 Romidepsin 60 Efficacy Trial 60 anticancer therapy 60 oropharyngeal candidiasis OPC 60 Colorectal Cancer Patients 60 Bevacizumab Avastin 60 relapsing remitting MS RRMS 60 BR.# 60 Mylan Receives Approval 60 Simulect 60 Onalta 60 Generic Version 60 Cloretazine R VNP#M 60 TO AVOID PREGNANCY WHILE 60 Fulvestrant 60 Onalta ™ 60 Demonstrates Significant 60 lexidronam injection 60 highly purified pasteurized 60 R bendamustine hydrochloride 60 dopamine partial agonist 60 Thrombin 60 Azedra 60 TRANSDUR ® 60 Initiate Phase 60 XYOTAX TM 60 PRN FDA Approves 60 Onyx Pharmaceuticals Announces 60 DexaSite 60 huC# DM4 60 ixabepilone 60 COPEGUS R 60 refractory metastatic colorectal cancer 60 Li Fraumeni Syndrome 60 HCV Protease Inhibitor 60 Neulasta ® 60 PKC# 60 Calcitonin 60 TYGACIL 60 Apaziquone 60 Liprotamase 60 Plicera 60 Cx# [002] 60 Gliadel Wafer 60 assessing T DM1 60 Cytarabine 60 Evoltra ® 60 Vitrasert R 60 MERREM 60 Tyrosine Kinase Inhibitor 60 COMFORT II 60 acute peripheral arterial 60 Hepatocellular Carcinoma HCC 60 Orphan Drug designation 60 GTC recombinant form 60 cMET 60 Taxotere docetaxel 60 radiation sensitizer 60 Bivalirudin 60 IAP inhibitors 60 SUTENT ® 60 Troxatyl 60 Elagolix 60 terlipressin 60 Modrenal R 60 Pegasys ® 60 THALOMID 60 INTEGRILIN 60 R rilonacept Injection 60 topically applied SEPA 60 HGS ETR1 mapatumumab 60 docetaxel Taxotere R 60 Patients Receiving 60 EGFR expressing metastatic colorectal 60 ganetespib 60 reslizumab 60 AzaSite Plus 60 Eculizumab 60 ara C 60 G#DT 60 NEUPOGEN R 60 galiximab 60 Well Tolerated 60 Product Characteristics 60 Lung Cancer Trial 60 HGS ETR1 60 Dupuytren Contracture 60 Clinical Trial Evaluating 60 Peginterferon Alfa 2a 60 sapropterin dihydrochloride Tablets 60 huN# DM1 60 stage IIIB 60 Fibrillex TM 60 L BLP# 60 biliary tract cancer 60 FDA Orphan Drug 60 immunotherapeutic agent 60 Shows Efficacy 60 Achieves Primary Endpoint 60 Nexavar prescribing 60 fosbretabulin 60 immunomodulatory therapy 60 Orally administered 60 ALVESCO R 60 Octreolin 60 Successfully Completes Phase 60 IMA# 60 Urocidin TM 60 ZACTIMA 60 Omacetaxine 60 JAK1 60 Solid Tumors 60 Trobalt 60 IV Busulfex 60 cutaneous T 60 PEG SN# 60 CINTREDEKIN BESUDOTOX 60 Warfarin Coumadin 60 successfully commercialize Iluvien 60 Pulmonary Arterial Hypertension 60 recurrent metastatic ovarian cancer 60 RNAi Therapeutic 60 R Bortezomib 60 Fludara 60 AzaSite Xtra 60 thetreatment 60 Jevtana 60 REVLIMID R 60 alfa 2a 60 Genasense ® oblimersen 60 Lung Cancer Drug 60 metastatic HRPC 60 cinacalcet 60 novel VDA molecule 60 SUTENT 60 bendamustine HCl 60 ELADUR TM 60 ALVESCO ® 60 Copegus R 60 Platinol ® 60 relapsed refractory multiple myeloma 60 Single Dose 60 Renal Function 60 Eluting Coronary Stent System 60 Ixabepilone 60 Therapy Evaluation 60 Initiates Phase II 60 systemic immunosuppressive drugs 60 Pfizer Sutent 60 evaluating Xcytrin 60 Initiates Clinical 60 Hedgehog Pathway Inhibitor 60 Randomized Phase II 60 Generx TM 60 Initiate Phase II 60 Inhalation Solution 60 Vascular Disrupting Agent 59 Intravenous Human 59 Marketing Authorization Application 59 low dose cytarabine 59 Investigational Agent 59 PROMACTA 59 lintuzumab SGN 59 GTC recombinant human 59 Alkeran 59 paclitaxel Taxol ® 59 LEP ETU 59 PI3K/Akt pathway inhibitor 59 ruxolitinib 59 Fast Track Designation 59 Allovectin 7 ® 59 dihydrochloride Tablets 59 Fluticasone 59 novel emulsion formulation 59 GAMMAGARD 59 memantine HCl 59 mertansine 59 LymphoStat B belimumab 59 kidney urologic 59 Thiarabine 59 Shows Statistically Significant 59 SANVAR 59 intravenous formulations 59 HuCAL PLATINUM ® CysDisplay 59 severe hypercholesterolemia 59 Temsirolimus 59 Octreotide 59 Neo Bladder Augment 59 Vicriviroc 59 Submits NDA 59 Allovectin 7 59 antibody MT# 59 First Patient Enrolled 59 ORENCIA R 59 adult chronic ITP 59 Phase Ib II 59 Pixantrone 59 GATTEX TM 59 HGS ETR2 59 R Saizen R 59 gemcitabine chemotherapy 59 Advanced Prostate Cancer 59 dirucotide MBP# 59 Announces Tentative Approval 59 Etanercept 59 BCG refractory carcinoma 59 Mycamine 59 TRISENOX ® 59 Parathyroid Hormone 59 ELACYT 59 Vitaxin 59 Advagraf 59 Cloretazine 59 SYCREST 59 VEGFR2 inhibitor 59 carcinoma HCC 59 Custirsen 59 Etoposide 59 systemic anaplastic large 59 Leukine ® 59 metastatic CRC 59 Allovectin 7 r 59 ARRY # 59 humanized anti 59 XL# XL# 59 Marketing Authorisation Application 59 Hypercholesterolemia 59 colesevelam HCl 59 Epirubicin 59 recurrent metastatic 59 Interferon beta 59 octreotide implant 59 Deferiprone 59 delivers fluocinolone acetonide FA 59 product candidate Lpathomab 59 forodesine 59 RAPTIVA 59 Phase 2a Clinical Trial 59 Ceflatonin 59 ® bortezomib 59 COPAXONE ® 59 Motesanib 59 label Lipofen R 59 ORENCIA ® 59 IAP inhibitor 59 CIMZIA ™ 59 personalized cellular immunotherapy 59 registrational trial 59 Factor VIIa 59 hA# 59 Expanded Indication 59 multiple myeloma MM 59 oral prodrug 59 Anti Bacterial Envelope 59 Phase 2b Trial 59 aflibercept VEGF Trap 59 BRIM2 59 refractory indolent non 59 FDA Approvals 59 PHX# 59 TRIOLEX HE# APOPTONE HE# 59 BRAF mutant 59 cetuximab Erbitux R 59 EndoTAG TM -1 59 BLP# Liposome Vaccine 59 Onconase 59 Doxil ® 59 REBETOL combination therapy 59 BRAF inhibitor 59 Cardium Therapeutics TM 59 Vidaza R 59 DEXILANT 59 ThermoDox ® 59 Elotuzumab 59 QUADRAMET R 59 TRACON Pharmaceuticals Inc. 59 TRANSDUR ™ 59 treatment naive genotype 59 EGFR HER2 59 efaproxiral 59 Ozarelix 59 tumors GIST 59 Solazed ™ 59 ONGLYZA ™ 59 StaphVAX R 59 BUPHENYL R 59 ISTODAX ® 59 Carfilzomib 59 Panzem 59 drug ISA# 59 erlotinib Tarceva R 59 tenofovir emtricitabine 59 CysDisplay R 59 Demonstrate Significant 59 Dabigatran etexilate 59 Glatiramer Acetate 59 VISICOL R 59 oncolytic virus therapies 59 Poly ICLC 59 APOPTONE 59 Lamictal ODT 59 Vidaza ® 59 infusional 5-FU/LV 59 HuMax TAC 59 ribavirin Copegus ® 59 ATL# [001] 59 Tolvaptan 59 modified glutathione analog 59 TLK# 59 HoFH 59 Ranolazine 59 MGd 59 trastuzumab DM1 T DM1 59 YERVOY 59 Dementia Related Psychosis 59 Traficet EN 59 Onco TCS 59 PEGINTRON TM 59 lapatinib Tykerb 59 hyperplasia BPH 59 Palifosfamide 59 metastatic castration resistant 59 castration resistant prostate cancer 59 GVAX ® 59 CIMZIA R 59 Panzem NCD 59 Mg Uk 59 oxaliplatin Eloxatin 59 arsenic trioxide injection 59 demonstrated antitumor activity 59 sapropterin dihydrochloride 59 vapreotide acetate 59 Luveniq 59 JAK Inhibitor 59 Prochymal TM 59 TKB# 59 hormone agonist 59 prGCD 59 Tekamlo 58 Darinaparsin 58 Mg Usa 58 Fibrin Pad 58 metaglidasen 58 topical gel formulation 58 5 FU leucovorin 58 anticancer compound 58 investigational pharmacologically unique 58 novel nucleoside analog 58 autologous cellular immunotherapy 58 Acute Attacks 58 phase III isavuconazole 58 plus dexamethasone 58 Psoriasis Drug 58 COLAZAL R 58 Annamycin 58 Thalomid ® 58 PEGASYS ® 58 ADVEXIN 58 CD# antibody [001] 58 OMAPRO ™ 58 Randomized Clinical Trial 58 Cleviprex TM clevidipine 58 evaluating T DM1 58 ocular formulation 58 cell lymphoma CTCL 58 Alocrest 58 Dupuytren Disease 58 Refractory Peripheral T 58 Completes Enrollment 58 gemcitabine Gemzar 58 Confirmatory Phase 58 lucinactant 58 CCR9 antagonist 58 TELINTRA 58 OMP #R# 58 CD# CEA 58 Resten NG 58 Interferon beta 1a 58 Liposomal 58 MEZAVANT R 58 molecular imaging radiopharmaceutical 58 Myocet 58 occlusion PAO 58 Mitoxantrone 58 Indaflex TM 58 IRX 2 58 silodosin 58 non nucleoside inhibitor 58 sunitinib malate 58 Anturol TM 58 omega interferon 58 markets HP Acthar 58 Solazed TM 58 Dose Ranging Study 58 Chemophase 58 advanced metastatic prostate 58 ceftazidime 58 OMNARIS HFA 58 Dyloject TM 58 MGN# 58 stage IIIb IV 58 thymosin alpha 1 58 INVEGA ® 58 SUMAVEL 58 Catena ® 58 TELCYTA 58 Fast Track designations 58 cIAI 58 Augment TM 58 Taxotere R 58 Telavancin 58 Preotact R 58 5 HT3 antagonist 58 Diamyd Medical Diamyd 58 5 fluorouracil leucovorin 58 XAGRID 58 Lenocta 58 Brilique 58 Cholesterol Lowering Drug 58 ANDA Filing 58 MOVIPREP R 58 metastatic gastric 58 OvaRex R 58 urocortin 2 58 BRILINTA 58 JAK2 Inhibitor 58 Levoleucovorin 58 sodium thiosulfate STS 58 Taliglucerase alfa 58 PEG INTRON 58 Aloxi R 58 Rebif ® 58 urethral bulking agent 58 INSPIRE Trial Phase III 58 telomerase therapeutic 58 brand ciclesonide HFA 58 INCB# [002] 58 Ophena TM 58 GVAX R 58 DepoBupivacaine TM 58 AMMONUL R 58 Talactoferrin 58 PROCRIT ® 58 PERLANE 58 metastatic malignant 58 Azilect ® 58 mitogen activated ERK kinase 58 Diovan Exforge Tekturna Zelnorm 58 amrubicin 58 TREDAPTIVE 58 Exemestane 58 Perforomist ™ Inhalation Solution 58 dose escalation clinical 58 Malignant Glioma 58 Bare Metal Stent 58 Soriatane 58 POSIDUR TM 58 malignant ascites 58 Submits Supplemental 58 Tyrima 58 LymphoStat B TM 58 non metastatic resectable 58 Schizophrenia Drug 58 oral deforolimus 58 overactive bladder syndrome 58 TM pralatrexate injection 58 BARACLUDE ® 58 alpha folate receptor 58 peptidic compound 58 Patient Outcomes 58 Release Capsules 58 RECOTHROM R 58 ALN TTR 58 Zirgan 58 VNP#M 58 JOULFERON 58 Keppra ® XR 58 Clevudine 58 Platelet Inhibition 58 ® lenalidomide 58 Topline Results 58 pioglitazone HCl 58 MYCAMINE 58 ALN HPN 58 CDK cyclin dependent 58 oral picoplatin 58 talactoferrin 58 Statistically Significant 58 Proxinium TM 58 CINQUIL 58 pertuzumab 58 Junovan 58 Bone Graft 58 lymphoma CTCL 58 cisplatin gemcitabine 58 Betaseron ® 58 DepoDur 58 Orphan Drug 58 vemurafenib 58 FOLOTYN 58 Inhalation Aerosol 58 samarium Sm 58 enzastaurin 58 Cytoxan ® 58 cintredekin besudotox 58 inhaled AAT 58 superficial basal cell carcinoma 58 oral aromatase inhibitor 58 intranasal formulation 58 Certolizumab pegol 58 Pathway Inhibitor 58 ARCOXIA 58 LHRH antagonist 58 capecitabine Xeloda 58 INCB# [001] 58 RhuDex TM 58 Soliris TM eculizumab 58 EVIZON TM 58 BrachySil TM 58 alvimopan 58 Amigal 58 small molecule Hedgehog 58 Treatment IND 58 treat chronic sinusitis 58 histone deacetylase inhibitor 58 pralatrexate injection folate analogue 58 Efficacy Results 58 TheraCIM 58 clofarabine 58 ALN PCS 58 EOquin 58 branded Rectogesic 58 refractory PTCL 58 VELCADE melphalan 58 catheter occlusion CO 58 INC# 58 registrational Phase 58 Exelixis XL# 58 rALLy 58 Tofacitinib 58 Ticagrelor 58 CA4P 58 antiangiogenesis therapies 58 Through Glycoscience 58 Bayer Onyx 58 DAVANAT R 58 Phase IIIb clinical 58 OMP #M# 58 PSMA ADC 58 Tostrex 58 RELISTOR ® 58 Kuvan TM sapropterin 58 neovascular age 58 oral Hsp# inhibitor 58 Emerging Therapies 58 lenalidomide Revlimid R 58 neratinib 58 rALLy clinical trial 58 Taiho Pharmaceutical 58 Presents Positive 58 rasagiline tablets 58 Recurrent Breast Cancer 58 mapatumumab 58 Iluvien ® 58 DAVANAT 58 oral iron chelator 57 Demonstrated Significant 57 Torisel 57 pegylated interferons 57 Genentech Rituxan 57 Certolizumab 57 Specifid 57 Leukine 57 Xcytrin R 57 Tanespimycin 57 Fodosine 57 investigational immunotherapy 57 ZOMIG R 57 REVLIMID ® 57 Soliris eculizumab 57 trastuzumab Herceptin 57 Study Showed 57 ferumoxytol Injection 57 Tolerability 57 SIR Spheres 57 peginterferon alfa 2a Pegasys 57 topoisomerase II inhibitor 57 candesartan cilexetil 57 RELOVAIR ™ 57 novel synthetic PEGylated 57 HRPC 57 Phase 1b Clinical Trial 57 Exherin 57 CIMZIA TM 57 methylnaltrexone 57 Actimmune ® 57 HuMax EGFr 57 COPEGUS 57 SNT MC# 57 leading oral taxane 57 SPL# Gel vaginal microbicide 57 ARIXTRA 57 hoFH 57 FavId 57 reduce serum phosphate 57 Nexavar sorafenib 57 evaluating tivozanib 57 ANYARA 57 sorafenib Nexavar ® 57 de novo kidney transplant 57 glufosfamide 57 EGRIFTA TM 57 SAR# [004] 57 XIENCE V Stent System 57 thymalfasin 57 PLK1 SNALP 57 Avastin bevacizumab 57 developing Bicifadine serotonin 57 pralatrexate 57 Begins Dosing 57 Serostim ® 57 GEM OS2 57 BRIM3 57 CYPHER R Sirolimus Eluting 57 Vascular Wrap TM 57 Orapred ODT 57 Trabectedin 57 dextromethorphan quinidine 57 Inhaled Corticosteroids 57 Peg IFN 57 PEGylated interferon 57 R pioglitazone HCl 57 Advaxis Phase 57 Diabetic Nephropathy 57 AMEVIVE 57 miconazole Lauriad ® 57 Prestara 57 anti inflammatory NSAID 57 Milestone Payments 57 Tesetaxel 57 esophageal candidiasis 57 complement inhibitor eculizumab 57 Eloxatin ® 57 Disease IBD 57 TRISENOX R 57 antibody MAb 57 HspE7 57 Triapine 57 alkylating agent 57 dual endothelin receptor antagonist 57 Arimidex anastrozole 57 DEB# 57 cutaneous T cell 57 Entereg R 57 MKC# MT 57 BCR ABL inhibitor 57 Augment Injectable 57 omacetaxine mepesuccinate 57 Bucindolol 57 glatiramer acetate 57 Testosterone Gel 57 PF # [002] 57 investigational oral inhibitor 57 NOTE POSIDUR ™ 57 investigational humanized monoclonal antibody 57 pemetrexed Alimta 57 Mutual Recognition Procedure 57 SABER ™ 57 Motexafin Gadolinium 57 Overactive Bladder 57 Nabi HB Intravenous 57 cetuximab Erbitux 57 MGCD# [001] 57 RoACTEMRA 57 Aptivus ®